krystexxa
crealta pharmaceuticals ireland limited - peglotika - dna - antiguty přípravky - krystexxa je indikován k léčbě závažné zneschopňující chronické tofózní dny u dospělých pacientů, kteří mohou mít erozivní společné zapojení a k normalizaci sérové hladiny kyseliny močové s inhibitory xanthinoxidázy maximální lékařsky dávky nebo pro koho jsou tyto léky kontraindikována.
tamsulosin hcl mylan 0,4mg tvrdá tobolka s řízeným uvolňováním
mylan ireland limited, dublin irsko - 14672 tamsulosin-hydrochlorid - tvrdá tobolka s řízeným uvolňováním - 0,4mg - tamsulosin
bisocard 10mg potahovaná tableta
bausch health ireland limited, dublin array - 10087 bisoprolol-fumarÁt - potahovaná tableta - 10mg - bisoprolol
bisocard 5mg potahovaná tableta
bausch health ireland limited, dublin array - 10087 bisoprolol-fumarÁt - potahovaná tableta - 5mg - bisoprolol
fenolax 5mg enterosolventní tableta
bausch + lomb ireland limited, dublin array - 174 bisakodyl - enterosolventní tableta - 5mg - bisakodyl
megace 40mg/ml perorální suspenze
bausch health ireland limited, dublin array - 885 megestrol-acetÁt - perorální suspenze - 40mg/ml - megestrol
progesteron besins 200mg měkká vaginální tobolka
besins healthcare ireland limited, dublin array - 1205 progesteron - měkká vaginální tobolka - 200mg - progesteron
progesteron besins 300mg měkká vaginální tobolka
besins healthcare ireland limited, dublin array - 1205 progesteron - měkká vaginální tobolka - 300mg - progesteron
vazkepa
amarin pharmaceuticals ireland limited - icosapent ethyl - dyslipidémie - Činidla modifikující lipidy - indicated to reduce cardiovascular risk as an adjunct to statin therapy.
kalydeco
vertex pharmaceuticals (ireland) limited - ivacaftor - cystická fibróza - jiné produkty dýchacích cest - kalydeco tablets are indicated:as monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cystic fibrosis transmembrane conductance regulator (cftr) gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 a 5. in a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who are homozygous for the f508del mutation or who are heterozygous for the f508del mutation and have one of the following mutations in the cftr gene: p67l, r117c, l206w, r352q, a455e, d579g, 711+3a→g, s945l, s977f, r1070w, d1152h, 2789+5g→a, 3272 26a→g, and 3849+10kbc→t. in a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (cf) who have at least one f508del mutation in the cftr gene (see section 5. kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (cf) who have an r117h cftr mutation or one of the following gating (class iii) mutations in the cftr gene: g551d, g1244e, g1349d, g178r, g551s, s1251n, s1255p, s549n or s549r (see sections 4. 4 a 5. in a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (cf) in paediatric patients aged 2 to less than 6 years who have at least one f508del mutation in the cftr gene.